Non-ICANS and Delayed Neurotoxicity With CAR T: Risk Factors and Ways to Prevent
July 14th 2025Panelists discuss emerging strategies to manage delayed neurotoxicity from chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, highlighting the predictive value of postinfusion lymphocyte expansion, the potential of early dexamethasone intervention, and the need for continued research and collaboration to refine toxicity prevention and ensure safer, broader use of CAR T in earlier treatment lines.
PERSEUS Trial: Progression-Free Survival
July 14th 2025Panelists discuss recent data showing that sustained minimal residual disease (MRD) negativity strongly predicts long-term progression-free survival (PFS) in multiple myeloma, regardless of whether patients receive a 4-drug daratumumab-based regimen or standard-drug therapy, emphasizing MRD negativity as a key surrogate end point; they also highlight challenges in predicting who benefits most from intensive therapy and the importance of individualized dosing strategies to balance efficacy and tolerability across different patient populations.
Role of CAR T in Earlier Lines for R/R MM
July 14th 2025Panelists discuss the growing support for incorporating chimeric antigen receptor (CAR) T-cell therapy earlier in the multiple myeloma treatment pathway, emphasizing the importance of timely referral and personalized decision-making to maximize patient outcomes before disease progression or comorbidities limit eligibility.
Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib
July 11th 2025Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures including dexamethasone premedication and dermatologic support, helps patients successfully tolerate amivantamab plus lazertinib therapy while maintaining treatment adherence.
Future of R/R MM: Emerging Bispecifics and Trispecifics
July 11th 2025Panelists discuss how the emerging trispecific antibody (targeting both T cells and natural killer [NK] cells) has generated significant excitement with its unprecedented 100% overall response rate in B-cell maturation antigen (BCMA)–exposed patients, while incorporating lessons learned from earlier bispecifics such as starting with Q4 weekly dosing and built-in tocilizumab prophylaxis, although they acknowledge this breakthrough may completely reshape treatment sequencing strategies and create new challenges in determining optimal therapy combinations.
From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC
July 11th 2025Panelists discuss how real-world experience with amivantamab plus lazertinib has shown remarkable responses consistent with trial data, including effectiveness in challenging cases like leptomeningeal disease, with manageable adverse effects when proper prophylactic measures and patient education are implemented.
What’s Next for Comprehensive Genomic Profiling in Cancer Care
July 10th 2025An expert discusses how comprehensive genomic profiling will continue growing as an essential component of personalized cancer care, expanding into serial testing for resistance monitoring, tumor burden tracking, and potentially earlier-stage cancers as targeted therapies prove effective beyond advanced disease.
Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
July 10th 2025An expert discusses how education about the clinical impact of genomic testing, understanding of targeted therapies, turnaround times, and team-based approaches are essential to bridge the gap in routine comprehensive genomic profiling adoption.
Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
July 10th 2025An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing help identify actionable genomic targets and monitor resistance patterns.
Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
July 10th 2025An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing helps identify actionable genomic targets and monitor resistance patterns.
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
July 9th 2025Panelists discuss how improving CAR T accessibility through reduced monitoring requirements could strengthen its position against bispecific antibodies in treatment decision-making, emphasizing that access considerations should only influence therapy choice when efficacy and safety are comparable, not when CAR T demonstrates superior outcomes.